Disclosures: Prajna Anirvan: Nothing to Disclose, Zaiba Khan: Nothing to Disclose, Pallavi Bhuyan: Nothing to Disclose, Sujata Dixit: Nothing to Disclose, Rishikesh Dash: Nothing to Disclose, Priyanka Mishra: Nothing to Disclose, Giriprasad Venugopal: Nothing to Disclose, Gowri Balachander: Nothing to Disclose, Pankaj Bharali: Nothing to Disclose, Mrinal Gogoi: Nothing to Disclose, Chitta Ranjan Khatua: Nothing to Disclose, Manas Panigrahi: Nothing to Disclose, Manoranjan Ranjit: Nothing to Disclose, Balamurugan Ramadass: Nothing to Disclose, Shivaram Singh: Boehringer Ingelheim International GmbH: Advisor, Sun Pharma: Stock - publicly traded company, Torrent Pharmaceuticals: Stock - publicly traded company, Dr Reddy's Labs: Stock - publicly traded company, Panacea Biotech Ltd: Stock - publicly traded company 606 BIOMARKER RESPONSE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) PATIENTS WITH HIGH-RISK BASELINE FAST SCORES: OBSERVATIONS FROM THE ENLIVEN PHASE2B TRIAL WITH PEGOZAFERMIN Cynthia Hartsfield 1 Naim Alkhouri 2 Quentin Anstee 3 Rohit Loomba 4 Manal Abdelmalek 5 Kris Kowdley 6 Maya Margalit 1 Mildred Gottwald 1 Germaine Agollah 1 Shibao Feng 1 Hank Mansbach 1 Arun Sanyal 7 , 1 89bio, 2 Arizona Liver Health, 3 Newcastle University, UK, 4 University of California, San Diego, 5 Mayo Clinic Rochester, 6 Liver Institute Northwest, 7 Virginia Commonwealth University Background: ENLIVEN was a 48-week study of the FGF21 analog, pegozafermin (PGZ), in subjects with biopsy-proven F2/F3 MASH
Sesamin attenuates histological alterations, oxidative stress and expressions of immune-related genes in liver of zebrafish (Danio rerio) exposed to fluoride
During the progression of AD, impaired compartmentalization of copper and zinc ions is one of the factors that trigger neuronal degeneration
A breathalyzer measures alcohol exhaled from your lungs reflecting your actual blood alcohol concentration (BAC) , not temporary mouth traces
